70) Structure–Activity Relationship and Bioactivity of Short Analogues of ELABELA as Agonists of the Apelin Receptor
Kien Trân, Alexandre Murza, Xavier Sainsily, Eugénie Delile, Pierre Couvineau, Jérôme Côté, David Coquerel, Maude Peloquin, Mannix Auger-Messier, Michel Bouvier, Olivier Lesur, Philippe Sarret and Éric Marsault
J.Med.Chem. , 2020, DOI: 10.1021/acs.jmedchem.0c01547

69) Gram‐scale Synthesis of Tomatidine, a Steroid Alkaloid with Antibiotic Properties Against Persistent Forms of Staphylococcus aureus.
Chad Normandin François Malouin Eric Marsault
Eur. J. Org. Chem. , 2020, 10.1002/ejoc.202000051

68) L-type prostaglandin D synthase regulates the trafficking of the PGD2 DP1 receptor by interacting with the GTPase Rab4.
Binda C; Génier S; Picard S; Degrandmaison J; Fréchette L; Jean S; Marsault E; Parent J-L
J. Biol. Chem. , 2019, 294, 16865-16883

67) The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders.
E Marsault, C Llorens-Cortes, X Iturrioz, H Chun, O Lesur, GY Oudit, M Auger-Messier
Ann. NY Acad. Sci. , 2019, 10.1111/nyas.14123

66) Discovery and Development of TMPRSS6 Inhibitors Modulating Hepcidin Levels in Human Hepatocytes.
F Béliveau; A Tarkar; MG Ghinet; SP Dion; PL Boudreault; A Désilets; C StGeorges; E Marsault; D Paone; J Collins; CH Macphee; N Campobasso; A Groy; J Cottom; M Ouellette; AJ Pope; R Leduc
Cell. Chem. Biol., 2019, S2451-9456

65) Simultaneous ligand and receptor tracking through NMR spectroscopy enabled by distinct 19F labels.
JR Simmons; A Murza; MD Lumsden; C Kenward; E Marsault; JK Rainey
Int. J. Mol. Sci., 2019; doi 10.3390/ijms20153658

64) Structural optimization and characterization of macrocyclic analogues of neurotensin 8-13.
M Sousbie; M Vivancos; E Besserer-Offroy; R Brouillette; JM Longpré; R Leduc; P Sarret; E Marsault
J. Med. Chem. , 2018, 61, 227-232

63) Peak AAA fatty acid homolog contaminants present in the dietary supplement l-Tryptophan associated with the onset of eosinophilia-myalgia syndrome.
Klarskov K, Gagnon H, Racine M, Boudreault P-L, Normandin C, Marsault É, Gleich G.J, Naylor S
Toxicology Letters. , 2018 May 294:193-204

62) A Systematic Exploration of Macrocyclization in Apelin-13: Impact on Binding, Signaling, Stability, and Cardiovascular Effects.
Trân K, Murza A, Sainsily X, Coquerel D, Côté J, Belleville K, Haroune L, Longpré JM, Dumaine R, Salvail D, Lesur O, Auger-Messier M, Sarret P, Marsault É
J Med Chem. , 2018 Mar 22;61(6):2266-2277

61) Apelins, ELABELA and their derivatives : peptidic regulators of the cardiovascular system and beyond.
Murza A, Trân K, Bruneau-Cossette L, Lesur O, Auger-Messier M, Lavigne P, Sarret P, Marsault E
Peptide Science – Special issue dedicated to Peptide Science in Canada, accepted 2018

60) Tomatidine, a lead antibiotic molecule that targets Staphylococcus aureus ATP synthase subunit C.
Lamontagne-Boulet M, Isabelle C, Guay I, Brouillette E, Langlois JP, Jacques PE, Rodrigue S, Brzezinski R, Beauregard PB, Bouarb K, Boyapelly K, Boudreault PL, Marsault E, Malouin F
Antimicrob. Agents Chemother, 2018, AAC.02197-17

59) The hypotensive effect of activated apelin receptor is correlated with β-arrestin recruitment.
Besserer-Offroy É, Bérubé P, Côté J, Murza A, Longpré JM, Dumaine R, Lesur O, Auger-Messier M, Leduc R, Marsault É, Sarret P.
Pharmacol Res accepted 02/2018, 131:7-16

58) In search of the optimal macrocyclization site for neurotensin.
Sousbie M, Besserer-Offroy E, Brouillette RL, Longpré JN, Leduc R, Sarret P, Marsault E.
ACS Med Chem Lett. 2018 Jan 29; 9(3):227-232

57) The apelinergic system as an alternative to catecholamines in low-output septic shock.
Coquerel D, Sainsily X, Dumont L, Sarret P, Marsault E, Auger-Messier M, Lesur O.
Crit. Care 2018, 22(1) 10

56) Purine analogs targeting the guanine riboswitch as potential antibiotics against Clostridioides difficile.
Yan LH, Le Roux A, Boyapelly K, Lamontagne AM, Archambault MA, Picard-Jean F, Lalonde-Seguin D, St-Pierre E, Najmanovich RJ, Fortier LC, Lafontaine D, Marsault É.
Eur J Med Chem. 2018, 1(143) 755-768

55) Targeting IL-5Rα with antibody-conjugates reveals a strategy for imaging and therapy for invasive bladder cancer
Paquette M, Vilera-Perez LG, Beaudoin S, Ekindi-Ndongo N, Boudreaut PL, Bonin MA, Battista MC, Bentourkia M, Lopez AF, Lecomte R, Marsault E, Guérin B, Sabbagh R, Leyton JV
Oncoimmunology, 2017, 6(10)

54) Structure Determination of Disease Associated Peak AAA from L-Tryptophan Implicated in the Eosinophilia-Myalgia Syndrome
Klarskov K, Gagnon H, Boudreault PL, Normandin C, Plancq B, Marsault E, Gleich GJ and Naylor S
Toxicol lett, 2017, 282, 71-80

53) Practical Medicinal Chemistry with Macrocycles (design, synthesis and case studies)
Edited by Éric Marsault and Mark Peterson
Wiley 2017, ISBN: 978-1-119-09256-8

52) The signaling signature of the neurotensin type 1 receptor with endogenous ligands
E Besserer-Offroy, R L Brouillette, S Lavenus, U Froehlich, A Brumwell, A Murza, J-M Longpré, E Marsault, M Grandbois, P Sarret, R Leduc
Eur J Pharmacol, 2017, 17, 30215-7

51) Elabela improves cardio-renal syndrome and outcome in fatal experimental septic shock
D Coquerel, F Chagnon, X Sainsily, L Dumont, A Murza, J Côté, R Dumaine, P Sarret, E Marsault, D Salvail, M Auger-Messier, O Lesur
Crit Care Med, 2017

50) Tomatidine and analog FC04-100 possess bactericidal activities against the small colony variants of some Firmicutes including those of Liseria monocytogenes and are bactericidal in combination with aminoglycosides against their normal phenotype
I Guay, S Boulanger, E Brouillette, F Chagnon, K Bouarab, E Marsault, F Malouin
submitted to BMC Complementary and Alternative Medicine, 02/2017

49) Modulating the selectivity of matriptase-2 inhibitors with unnatural amino acids
C St-Georges, A Désilets, F Béliveau, M Ghinet, SP Dion, É Colombo, PL Boudreault, RJ Najmanovich, R Leduc, and E Marsault
Eur J Med Chem, 2017, 129, 110-123

48) Synthesis and characterization of a phosphate prodrug of isoliquiritigenin
K Boyapelly, MA Bonin, H Traboulsi, A Cloutier, SC Phaneuf, D Fortin, A Cantin, M Richter, E Marsault
J Nat Prod, 2017, 80 (4), 879-886

47) Modular sub-monomeric cell-penetrating peptoids – Synthesis, assembly and biological evaluation
E Marouseau, A Neckebroeck, H Larkin, A Le Roux, L Volkov, C Lavoie, E Marsault
RSC Advances, 2017, 7, 6059-6063

46) Structure–activity relationship of novel macrocyclic biased apelin receptor agonists
Alexandre Murza, Xavier Sainsily, Jérôme Côté, Laurent Bruneau-Cossette, Élie Besserer-Offroy, Jean-Michel Longpré, Richard Leduc, Robert Dumaine, Olivier Lesur, Mannix Auger-Messier, Philippe Sarret and Éric Marsault
Org. Biomol. Chem. 2017, 15, 449-458

45) Design, synthesis, and biological evaluation of CXCR4 ligands
Christine E. Mona, Élie Besserer-Offroy, Jérôme Cabana, Richard Leduc, Pierre Lavigne, Nikolaus Heveker, Éric Marsault, Emanuel Escher
Org. Biomol. Chem. 2016, 14, 10298-10311

44) Bis-Michael Acceptors as Novel Probes to Study the Keap1/Nrf2/ARE Pathway
Ludovic J. Deny, Hussein Traboulsi, André M. Cantin, Eric Marsault, Martin V. Richter, Guillaume Bélanger
J. Med. Chem. 2016 59 (20), 9431–9442

43) Apelin Compared With Dobutamine Exerts Cardioprotection and Extends Survival in a Rat Model of Endotoxin-Induced Myocardial Dysfunction.
Chagnon, Frederic; Coquerel, David; Salvail, Dany; Marsault, Eric; Dumaine, Robert; Auger-Messier, Mannix; Sarret, Philippe; Lesur, Olivier
Crit Care Med, 2016 [Epub ahead of print]

42) Matriptase regulates c-Met mediated proliferation and invasion in inflammatory breast cancer
Gina L. Zoratti, Lauren M. Tanabe, Thomas E. Hyland, Michael J. Duhaime, Éloïc Colombo, Richard Leduc, Eric Marsault, Michael D. Johnson, Chen-Yong Lin, Julie Boerner, Julie E. Lang, Karin List
Oncotarget, 2016 7 (36), 58162-58173

41) Structure Activity Relationship and Signaling of New Chimeric CXCR4 Agonists
Christine E Mona, Élie Besserer-Offroy, Jérôme Cabana, Marilou Lefrançois, Philip E. Boulais, Marie-Reine Lefebvre, Richard Leduc, Pierre Lavigne, Nikolaus Heveker, Eric Marsault, Emanuel Escher
J. Med. Chem., 2016 59 (16), 7512-7524

40) Intracuff 160 mg alkalinized lidocaine reduces cough upon emergence from N2O-free general anesthesia: a randomized controlled trial.
Houssine Souissi, Yannick Fréchette, Alexandre Murza, Marie-Hélène Masse, Éric Marsault, Philippe Sarret, Frédérick D’Aragon, Alexandre J. Parent, Yanick Sansoucy
Can J Anaesth., 2016 63 (7) 862-870

39) Discovery and Structure-Activity Relationship of a Bioactive Fragment of ELABELA that Modulates Vascular and Cardiac Functions.
A Murza, X Sainsily, D Coquerel, J Côté, P Marx, É Besserer-Offroy, J-M Longpré, J Lainé, B Reversade, D Salvail, R Leduc, R Dumaine, O Lesur, M Auger-Messier, P Sarret, E Marsault
J. Med. Chem., 2016 59 (7), 2962-2972

38) The Flavonoid Isoliquiritigenin Reduces Lung Inflammation and Mouse Morbidity during Influenza Infection.
H Traboulsi, A Cloutier, K Boyapelly, MA Bonin, E Marsault, AM Cantin, MV Richter
Antimicrobial Agents and Chemoterapy, 2015, 59 (10), 6317-27

37) Smart imaging of acute lung injury: validation of myeloperoxidase (MPO) activity using in vivo endoscopic confocal fluorescence microscopy (ECFM).
F Chagnon, A Bourgouin, R Lebel, MA Bonin, E Marsault, M Lepage, O Lesur
Am J Physiol Lung Cell Mol Physiol, 2015, 309 (6), 543-51

36) Solid phase parallel synthesis of functionalized medium-to-large cyclic peptidomimetics via three-component coupling driven by aziridine aldehyde dimers.
AP Treder, MC Tremblay, J Hickey, S Zaretsky, J Mancuso, C Scully, A Doucet, A Yudin, E Marsault
Chemistry, 2015, 21 (25), 9249-55

35) Targeting matriptase in breast cancer abrogates tumour progression via impairment of stromal-epithelial growth factor signalling.
GL Zoratti, LM Tanabe, FA Varela, AS Murray, C Bergum, E Colombo, JE Lang, AA Molinolo, R Leduc, E Marsault, J Boerner, K List
Nat. Commun., 2015, 6, 6776

34) Macrocyclic cell penetrating peptides: a study of structure-penetration properties.
Traboulsi H, Larkin H, Bonin MA, Volkov L, Lavoie C, Marsault E
Bioconjugate Chemistry, 2015, 26 (3), 405-11

33) C-terminal Modifications of apelin-13 significantly change ligand binding, receptor signaling and hypotensive action.
Murza A, Besserer-Offroy E, Côté J, Bérubé P, Longpré JM, Dumaine R, Lesur O, Auger-Messier M, Leduc R, Sarret P, Marsault E
J. Med. Chem, 2015, 58 (5), 2431--2440

32) Analysis of sub-pocket druggability and detection of potent selective inhibitors of the matriptase-2 human protease.
D Duchêne, E Colombo, A Désilets, R Leduc, E Marsault, R Najmanovich
J. Med. Chem, 2014, 57 (23), 10198--10204

31) One-pot synthesis of polyunsaturated fatty acid amides with anti-proliferative properties.
Tremblay H, St-Georges C, Legault MA, Morin C, Fortin S, Marsault E
Bioorg. Med. Chem. Lett. 2014, 24 (24), 5635–5638

30) Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties.
Demeule M, Beaudet N, Régina A, Besserer-Offroy É, Murza A, Tétreault P, Belleville K, Ché C, Larocque A, Thiot C, Béliveau R, Longpré JM, Marsault É, Leduc R, Lachowicz JE, Gonias SL, Castaigne JP, Sarret P
J. Clin. Invest. 2014, 124 (3) 1199–1213

29) Solid-phase synthesis of piperazinones via disrupted Ugi condensation.
Treder AP, Tremblay MC, Yudin AK, Marsault E
Org. Lett. 2014, 16 (17), 4674–4677

28) Unraveling the structure–activity relationship of tomatidine, a steroid alkaloid with unique antibiotic properties against persistent forms of Staphylococcus aureus.
F Chagnon, I Guay, MA Bonin, G Mitchell, K Bouarab, F Malouin, E Marsault
Eur. J. Med. Chem. 2014, 80 (10), 605--620

27) Macrocycles as templates for diversity-oriented synthesis in Diversity-Oriented Synthesis
Marsault E
Wiley, A. Trabocchi Ed, 2013

26) Stability and degradation patterns of chemically modified analogs of apelin-13 in plasma and cerebrospinal fluid.
A Murza, K Belleville, JM Longpré, P Sarret, E Marsault
Biopolymers Pept Sci, 2014, 102 (4) 297--303

25) Efficient synthesis of 2-ureaguanines via 2-isocyanatopurines and in situ reaction with amines.
A Le Roux, E Marsault
Synthesis. 2013, 45, 1983-1990

24) Use of macrocycles exemplified with Ulimorelin, a ghrelin agonist for the potential treatment of gastrointestinal motility disorders.
Peterson ML; Fraser GL; Hoveyda HR; Marsault E ; Gagnon R
Analogues-based drug discovery III (IUPAC Series); J Fischer, CR Ganellin, DP Rotella Eds (Wiley), 2013

23) Matriptase proteolytically activates influenza virus and promotes multicycle replication in the human airway epithelium.
A Beaulieu, E Gravel, A Cloutier, I Marois, E Colombo, A Désilets, C Verreault, R Leduc, E Marsault, MV Richter
J. Virol. 2013, 87, 8

22) Experimental treatment of Staphylococcus aureus bovine intramammary infection using PC1, a guanine riboswitch ligand analog.
C Ster, M Allard, S Boulanger, M Lamontagne Boulet, J Mulhbacher, DA Lafontaine, E Marsault, P Lacasse, F Malouin
J Dairy Sci 2012, 96, 2

21) Design and synthesis of new, selective inhibitors of matriptase.
E Colombo; F Chagnon; A Désilets; D Duchêne; R Najmanovich; R Leduc; E Marsault
ACS Med Chem Lett. 2012, 3, 530

20) Tomatidine acts in synergy with aminoglycoside antibiotics against multiresistant Staphylococcus aureus and prevents virulence gene expression.
G Mitchell; M Lafrance; S Boulanger; D Lalonde Séguin; I Guay; M Gattuso; E Marsault; K Bouarab; F Malouin
J Antimicrob Chemother. 2012, 67, 559.

19) Elucidation of the structure-activity relationships of apelin: influence of unnatural amino acids on binding, signaling, and plasma stability.
Murza A; Parent A; Besserer-Offroy E; Tremblay H; Karadereye F; Beaudet N; Leduc R; Sarret P; Marsault É.
ChemMedChem 2012, 7, 318.

18) Optimization of a Macrocyclic Ghrelin Receptor Agonist: Development of Ulimorelin (TZP-101) from Hit to Clinic.
HR Hoveyda; E Marsault; R Gagnon; AP Mathieu; M Vézina; A Landry; Z Wang; K Benakli; S Beaubien; C Saint-Louis; M Brassard; JF Pinault; L Ouellet; S Bhat; M Ramaseshan; X Peng; L Foucher; S Beauchemin; P Bhérer; DF Veber; ML Peterson; GL Fraser
J Med Chem, 2011, 54, 8305.

17) Tomatidine inhibits the replication of staphylococcus aureus Small-Colony Variant in cystic fibrosis airway epithelial cells.
G Mitchell; M Gattuso; G Grondin; E Marsault; K Bouarab; F Malouin
Antimicrob. Agents Chemother 2011, 1937

16) Macrocycles are great cycles: applications, challenges and opportunities of synthetic macrocycles in drug discovery.
E Marsault; ML Peterson
J. Med. Chem. 2011, 54, 1961.

15) From libraries of macrocyclic peptidomimetics to gastrointestinal drugs.
Peterson ML; Fraser GL; Hoveyda HR; Marsault E; Thomas H
Biopolymers 2009, 92, 299.

14) High throughput solid phase parallel synthesis of macrocyclic peptidomimetics.
Marsault E; Hoveyda HR; Peterson ML; Gagnon R; Vézina M; Pinault JF; Landry A; Saint-Louis C; Ouellet LG; Beauchemin S; Benakli K; Beaubien S; Brassard M; Wang Z; Champagne M; Galaud F; Fortin N; Fortin D; Plourde V; Ramaseshan M; Bhat S; Bilodeau F; Lonergan D; Lan R; Li, S; Berthiaume G; Foucher L; Peng X; Dory Y; Deslongchamps P
Adv Exp Med Biol 2009, 611, 15.

13) Parallel solid-phase synthesis of macrocyclic peptidomimetics using Ru-catalyzed ring-closing metathesis and a new application of cross metathesis.
Beaubien S; Hoveyda HR; Vézina M; Marsault E; Tremblay H; Foucher L; Benakli K
Adv Exp Med Biol 2009, 611, 13.

12) Efficient parallel synthesis of macrocyclic peptidomimetics.
Marsault E; Hoveyda HR; Gagnon R; Peterson ML; Vézina M; Saint-Louis C; Landry A; Pinault JF; Ouellet L; Beauchemin S; Beaubien S; Mathieu A; Benakli K; Wang Z; Brassard M; Lonergan D; Bilodeau F; Ramaseshan M; Fortin N; Lan R; Li S; Galaud F; Plourde V; Champagne M; Doucet A; Bhérer P; Gauthier M; Olsen G; Villeneuve G; Bhat S; Foucher L; Fortin D; Peng X; Bernard S; Drouin A; Déziel R; Berthiaume G; Dory YL; Fraser GL; Deslongchamps P
Bioorg Med Chem Lett 2008, 18, 4731.

11) The ghrelin receptor agonist TZP-101 is a potent anti-tumor-cachexia agent in the human G361 melanoma mouse xenograft model.
Thomas H; Berthiaume N; Kneebone E; Clohs L; Fournier E; Peterson ML; Marsault E; Brandt R
Eur. J. Can. 2008, 6, 107.

10) The motilin receptor antagonist TZP-201 is highly effective in the control of irinotecan-induced diarrhea in beagle dogs.
Thomas H; Chen C; Marsault E
Mol Can Ther 2007, 6, 3606S.

9) The motilin receptor antagonist TZP-201 is highly effective in the control of irinotecan-induced diarrhea in beagle dogs.
Thomas H; Chen C; Marsault E
Neurogastr Motil 2007, 19, 35.

8) Potent macrocyclic antagonists to the motilin receptor presenting novel unnatural amino acids.
Marsault E; Benakli K; Ouellet L; Beaubien S; Saint-Louis C; Déziel R; Fraser GL
Bioorg Med Chem Lett 2007, 17, 4187.

7) Discovery of a new class of macrocyclic antagonists to the human motilin receptor.
Marsault E; Hoveyda HR; Peterson ML; Saint-Louis C; Landry A; Vézina M. Ouellet L; Wang, Z; Ramaseshan M; Beaubien S; Benakli K; Beauchemin S; Déziel R; Peeters T; Fraser GL
J Med Chem 2006, 49, 7190.

6) Increasing the efficiency of the transannular Diels-Alder strategy via stille macrocyclizations.
Marsault E; Deslongchamps P
Org Lett 2000, 2, 3317.

5) The transannular Diels-Alder reaction: applications to total synthesis.
Marsault E; Toró A; Nowak P; Deslongchamps P; Tetrahedron report
Tetrahedron 2001, 57, 4243.

4) Total synthesis of 3-azasteroids via the transannular Diels-Alder strategy.
Fortin D; Gaudette F; Marsault E; Deslongchamps P
Tetrahedron 2001, 57, 4167.

3) Imidazo-oxazaphosphorines as precursors to chiral phosphite triesters.
Marsault E; Just G
Nucleosides & Nucleotides 1998, 17, 939.

2) Oxazaphosphorinane precursors to the diastereoselective synthesis of DNA phosphorothioates.
Marsault E; Just G
Tetrahedron 1997, 53, 16945.

1) Diastereoselective synthesis of phosphite triesters through a new bicyclic intermediate.
Marsault E; Just G
Tetrahedron lett. 1996, 37, 977.